GSK Reports Positive Results For Jemperli Trial In Endometrial Cancer

Follow us on Google News:
 GSK Reports Positive Results For Jemperli Trial In Endometrial Cancer
Image source: ©2022 Kalkine Media®

Dec 2 (Reuters) - GSK PLC


* JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER

* GSK: JEMPERLI (DOSTARLIMAB) RUBY PHASE III TRIAL MET ITS PRIMARY ENDPOINT

* RESULTS SHOWED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN INVESTIGATOR-ASSESSED PROGRESSION-FREE SURVIVAL

* REGULATORY SUBMISSIONS BASED ON TRIAL RESULTS ARE PLANNED FOR FIRST HALF OF 2023 Source text for Eikon:

Disclaimer

The above content is directly sourced from Reuters under a contractual arrangement. The content is being provided as a convenience and for informational purposes only; and does not constitute an endorsement or approval by Kalkine Media of any of the products, services, or opinions of the organization or individual. The user is apprised that Kalkine Media bears no responsibility for the accuracy, legality, or content of Reuters, any external sites, or for that of subsequent links. The user is requested to contact Reuters directly for answers to questions regarding the content. Please note that Kalkine Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Featured Articles